沛嘉醫療-B(09996.HK)經房間隔二尖瓣置換系統完成亞洲首例植入
沛嘉醫療-B(09996.HK)公佈,沛嘉之HighLife經房間隔二尖瓣置換(TSMVR)系統科研臨牀試驗已於內地招募首名患者。於2021年12月22日,中國四川大學華西醫院教授陳茂及其團隊成功完成首例植入。公司之外部顧問加拿大蒙特利爾麥吉爾大學心臟病介入專家醫生Nicolo Piazza通過遠程視頻在線指導手術過程。這是亞洲完成之首例TSMVR系統植入。
此外,於12月18日,公司與法國醫療器械公司HighLife SAS訂立許可協議,據此,HighLife SAS已就大中華地區的若幹專有經導管二尖瓣置換術(TMVR)產品向公司授出獨家許可。技術轉讓已於2021年第三季完成,並已建立內地本土製造設施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.